Furthermore, in addition to being well-tolerant to CL-siSOX2, the mice also show fewer side effects and decreased tumor size in the combination treatment group of CL-siSOX2 and cisplatin, which provides an effective SOX2-targeted strategy for lung cancer, either monotherapy or in combination with cisplatin [171]. The gene discussed is SOX2; the disease is lung cancer.